SRT3

211.6

-2.11%↓

ORNBV.FI

67.34

0%↓

PHMA

96.7

+1.15%↑

DRW3

84.9

-2.64%↓

SRT3

211.6

-2.11%↓

ORNBV.FI

67.34

0%↓

PHMA

96.7

+1.15%↑

DRW3

84.9

-2.64%↓

SRT3

211.6

-2.11%↓

ORNBV.FI

67.34

0%↓

PHMA

96.7

+1.15%↑

DRW3

84.9

-2.64%↓

SRT3

211.6

-2.11%↓

ORNBV.FI

67.34

0%↓

PHMA

96.7

+1.15%↑

DRW3

84.9

-2.64%↓

SRT3

211.6

-2.11%↓

ORNBV.FI

67.34

0%↓

PHMA

96.7

+1.15%↑

DRW3

84.9

-2.64%↓

Inicio・Lista de Acciones・Sanofi SA

Search

Sanofi SA

Abierto

SectorSanidad

73.02 -0.5

Resumen

Variación precio

24h

Actual

Mínimo

71.78

Máximo

73.42

Métricas clave
By Trading Economics
Ingresos	-394M 1.6B
Ventas	-12B 11B
P/B Media del Sector	20.158 49.8
BPA	1.34
Margen de beneficios	14.354
Empleados	74,846
EBITDA	1.5B 2.7B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+28.17% upside

Dividendos
By Dow Jones
Próximas Ganancias	30 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-5.1B 94B
Apertura anterior	73.52
Cierre anterior	73.02

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

119 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

91.3 / 96.1 Soporte y Resistencia

Sanofi SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 abr 2026, 09:03 UTC

Ganancias

Spain's Santander Profit Climbs Amid Global Portfolio Reshuffle -- Update

29 abr 2026, 05:27 UTC

Ganancias

Santander Books Jump in Profit on Top-Line Growth, Lower Costs

23 abr 2026, 06:12 UTC

Ganancias

Sanofi Posts Higher Sales Amid Leadership Transition

7 may 2026, 06:47 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

1 may 2026, 06:14 UTC

Adquisiciones, fusiones, absorciones

Santander UK to Also Pay GBP213M Based on TSB's Tangible NAV

1 may 2026, 06:13 UTC

Adquisiciones, fusiones, absorciones

Santander UK Also Financed Deal From Funding by Parent, Banco Santander

1 may 2026, 06:12 UTC

Adquisiciones, fusiones, absorciones

Santander UK Financed Deal From Existing Cash Resources

1 may 2026, 06:08 UTC

Adquisiciones, fusiones, absorciones

Santander UK Announced Key Terms of Deal July 2025

1 may 2026, 06:03 UTC

Adquisiciones, fusiones, absorciones

Santander UK Buys TSB Banking for GBP2.65B

1 may 2026, 06:02 UTC

Adquisiciones, fusiones, absorciones

Santander UK Buys TSB Banking Group

29 abr 2026, 12:01 UTC

Ganancias

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

29 abr 2026, 06:27 UTC

Charlas de Mercado

Ganancias

Santander's Above-Forecast Earnings Should Be Well-Received -- Market Talk

29 abr 2026, 04:55 UTC

Ganancias

Analysts Saw Santander 1Q Loan Loss Provisions EUR3.12B

29 abr 2026, 04:55 UTC

Ganancias

Santander 1Q Loan Loss Provisions EUR3.225B

29 abr 2026, 04:54 UTC

Ganancias

Analysts Saw Santander 1Q Operating Expenses EUR6.57B

29 abr 2026, 04:54 UTC

Ganancias

Santander 1Q Operating Expenses EUR6.48B

29 abr 2026, 04:52 UTC

Ganancias

Santander Backs 2028 View

29 abr 2026, 04:52 UTC

Ganancias

Santander Backs 2026 View

29 abr 2026, 04:52 UTC

Ganancias

Santander 1Q Underlying RoTE 15.2%

29 abr 2026, 04:51 UTC

Ganancias

Santander End-1Q CET1 Ratio 14.4%

29 abr 2026, 04:51 UTC

Ganancias

Analysts Saw Santander 1Q Net Interest Income EUR10.86B

29 abr 2026, 04:51 UTC

Ganancias

Santander 1Q Net Interest Income EUR11.02B

29 abr 2026, 04:50 UTC

Ganancias

Analysts Saw Santander 1Q Underlying Net Pft EUR3.47B

29 abr 2026, 04:50 UTC

Ganancias

Santander 1Q Underlying Pft EUR3.56B

29 abr 2026, 04:49 UTC

Ganancias

Santander 1Q Net Pft EUR5.455B

29 abr 2026, 04:49 UTC

Ganancias

Analysts Saw Santander 1Q Rev EUR15.00B

29 abr 2026, 04:49 UTC

Ganancias

Santander 1Q Rev EUR15.14B

27 abr 2026, 09:32 UTC

Charlas de Mercado

Ganancias

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

27 abr 2026, 09:19 UTC

Charlas de Mercado

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

23 abr 2026, 05:34 UTC

Ganancias

Sanofi: 2026 Expectations Are at Constant Exchange Rates

Comparación entre iguales

Cambio de precio

Sanofi SA previsión

Precio Objetivo

By TipRanks

28.17% repunte

Estimación a 12 Meses

Media 93.696 EUR 28.17%

Máximo 107 EUR

Mínimo 80 EUR

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

4

Comprar

6

Mantener

0

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Sanofi SA Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

91.3 / 96.1Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentimiento

By Acuity

119 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Otras acciones del sector

SRT3

Sartorius AG

211.6

ORNBV.FI

Orion Oyj (Class B)

67.34

PHMA

Pharma Mar SA

96.7

DRW3

Draegerwerk AG & Co KGaA- PREF

84.9

Live chat